Skip to main content

Soon we will have cancer vaccines created under genomic guidance: Dr Pramod K Srivastava

Soon we will have cancer vaccines created under genomic guidance: Dr Pramod K Srivastava

In an interview with ETHealthworld, Dr Pramod K Srivastava, Prof & Director of the Centre for Immunotherapy of Cancer & Infectious Diseases, Connecticut, US, talks about the role and opportunities in genomic research and the making of cancer vaccine.

You have been associated with clinical research right from the 90s. Tell us about the opportunities that genomics offers today?

Around 1990's there was no genomics in cancer immunology or cancer immunotherapy. The whole idea of genomics coming into it has come about only in the last 5 or 6 years because only then could we look at the entire genome of a patient.

What we can do today is to take the cancer of a patient, take their normal tissues and read the entire genome both normal and the cancerous within a week and we can compare how it is different within another week. So basically in two weeks time in surgery or from biopsy we can pinpoint all the positions where this cancer is different from the normal tissue.

This capacity didn't exist in a practical way until 2008-2009 but now sequenced genome is pretty much at the cost of a MRI scan, little more than that. Today, it is like a whole different world with different languages, different level of precision and different levels of possibilities.

Can cancer vaccine be a reality today?

Cancer vaccines are certainly not a reality today but it could they be a reality in 10 years time. It is not a question of if but it is a question of when and how and where. The way we treat cancer today is not very effective.

Today in terms of outcome there isn't much of difference and the reason is that the things that we use for these treatments like chemotherapy and surgery they don't discriminate between normal tissues and cancers in any real way. It kills cancers and normal tissues also and the whole goal is to traverse that very normal lane and damage the cancer more than damaging the normal tissue.



ᐧ
ᐧ

Comments

Popular posts from this blog

Registration of herbal trials in CTRI is not mandatory

A trial patient visited the site complaining breathlessness and tachycardia. The investigator advised hospitalization but as subject could not afford the expenses, he refused for admission. Is this an SAE because investigator advised hospitalization? G Praveen Kumar. If the patient was not hospitalized, it does not fall into SAE criteria of hospitalization. However, it appears from your mail that the PI felt that the event was serious enough to admit the subject for treatment. This makes it an “important medical event." As per ICH E2A such event also are considered serious. See the ICH E2A excerpt below: Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the defin...

Evidence for Atypical Antipsychotic Drugs Called into Question

Despite massive advertising and booming prescriptions, use and sales, the new atypical antipsychotic medications such as Seroquel and Abilify – used to treat schizophrenia , bipolar disorder, depression and other illnesses – lack sufficient evidence to support their widespread and generalized usage. This according to a new study out of the Stanford University School of Medicine and University of Chicago. In the past decade, atypical antipsychotics have rocketed past many commonly prescribed, but older antidepressant and other psychiatric medications. Although initially touted as having few side effects, followup studies have found that atypical antipsychotics have serious side effects, including significant weight gain that can lead to diabetes and heart disease. “Because these drugs have safety issues, physicians should prescribe them only when they are sure patients will get substantial benefits,” said Randall Stafford, M.D., Ph.D., a Stanford associate pro...

In India, there is no separate guidance on pregnancy reporting

How will we conclude that the subject is illiterate? Dr Prakash Atlam The guidelines don’t use the term illiterate. Their focus is subject’s ability to read and/or write. Schedule Y treats anyone who is unable to read or write in the same way. See the excerpt below. If the subject or his/her legally acceptable representative is unable to read/write - an impartial witness should be present during the entire informed consent process who must append his/her signatures to the consent form. While designing a protocol we found that there are high likely chances of worsening of some of the symptoms. Do we have to wait for these to happen and report it as SAE or in case we define them in the protocol upfront then can we prevent from expediting reporting it as SAE? Om Please see suggested guidance from ICH. Exemption from reporting such events would require prior agreement with regulatory authorities. ICH E3 12.2.2 Display of Adverse Events: All adverse events occurrin...